Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... April 21, 2026 FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... March 18, 2021 10 Things I Wish I Knew When I Was First Diagnosed... July 19, 2022 Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish... May 5, 2026 Load more HOT NEWS Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... FDA Approvals Expand Initial Treatment Options for Multiple Myeloma Two Women With Terminal Breast Cancer Started A Podcast That’s Unflinchingly... Alectinib Approved as an Adjuvant Treatment for Lung Cancer
